21/10/2018 Relação de conversão entre Dysport e Botox na prática clínica: uma visão geral das evidências disponíveis | SpringerLink

Relação de conversão entre Dysport e
Botox na prática clínica: uma visão geral
das evidências disponíveis
Ciências Neurológicas

Julho de 2013, Volume 34, edição 7 , pp 1043-1048 | Citar como

Roberta Ravenni (1) Autor de email (rravenni.md@libero.it)

Domenico De Grandis (2) 
Alberto Mazza (3) 

1.  Departamento de Neurociências, Neurologia e Neurofisiologia Unidades , Ospedale

Civile Santa Maria da Misericórdia Hospital , , Rovigo , Itália
2.  UILDM , , Verona , Itália
3.  Departamento de Medicina Interna , Santa Maria della Misericordia Hospital , ,
Rovigo , Itália

Artigo de Revisão
Primeiro online: 11 de abril de 2013

7 ações
877 Transferências
12 Citações

Abstrato

A relação de conversão ótima entre Dysport e Botox - os dois produtos da neurotoxina

botulínica do tipo A (BoNT-As) apoiados pelo maior volume de evidências - tem sido
amplamente debatida, devido às suas amplas implicações médicas e econômicas. O
artigo discute as evidências disponíveis sobre a relação de conversão entre Dysport e
Botox em adultos afetados por espasticidade, distonia cervical, blefaroespasmo e
espasmo hemifacial, com foco em ensaios clínicos que abordaram especificamente esta
questão. Além disso, algumas sugestões sobre a taxa de conversão entre Dysport e
Xeomin podem ser extrapoladas, uma vez que o Xeomin tem o mesmo perfil de
eficácia e segurança que o Botox e é trocável com o Botox com uma taxa de conversão
de 1: 1. Tomados em conjunto, os resultados obtidos a partir desta pesquisa
bibliográfica sugerem que uma taxa de conversão de 3: 1 (Dysport: Botox) - ou ainda
mais baixo - pode ser considerado apropriado para o tratamento das condições acima
mencionadas. Razões de conversão mais elevadas podem levar a uma sobredosagem
de Dysport, com um potencial aumento da incidência de eventos adversos. Portanto,
recomendamos que os médicos que usam ambos os produtos considerem usar um
fator de conversão mais baixo como guia, ajustando-o para cima conforme necessário,
com base nas características específicas e na resposta ao tratamento de cada paciente.

https://link.springer.com/article/10.1007/s10072-013-1357-1 1/9
21/10/2018 Relação de conversão entre Dysport e Botox na prática clínica: uma visão geral das evidências disponíveis | SpringerLink

Palavras­chave
Blefaroespasmo  Toxina botulínica  Distonia cervical  Relação de conversão 
Espasmo hemifacial  Espasticidade 
Esta é uma prévia do conteúdo da assinatura, efetue login para verificar o acesso.

Notas

Acknowledgments

Editorial assistance was provided by Luca Giacomelli, PhD, on behalf of inScience

Communications, Springer Healthcare. This assistance was funded by Ipsen.

Conflict of interest

  Authors declare no conflicts of interest directly relevant to this study.

Referências
1. De Maio M (2008) Therapeutic uses of botulinum toxin: from facial palsy to
autonomic disorders. Expert Opin Biol Ther 8:791–798
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18476790)
CrossRef (https://doi.org/10.1517/14712598.8.6.791)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Therapeutic%20uses%20of%20botulinum%20toxin%3A%20from%20faci
al%20palsy%20to%20autonomic%20disorders&author=M.%20Maio&journal=
Expert%20Opin%20Biol%20Ther&volume=8&pages=791-
798&publication_year=2008)
2. Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB (2010) International
consensus statement for the use of botulinum toxin treatment in adults and
children with neurological impairments—introduction. Eur J Neurol 17(Suppl
2):1–8
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20633176)
CrossRef (https://doi.org/10.1111/j.1468-1331.2010.03125.x)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=International%20consensus%20statement%20for%20the%20use%20of%
20botulinum%20toxin%20treatment%20in%20adults%20and%20children%2
0with%20neurological%20impairments%E2%80%94introduction&author=A.
%20Esquenazi&author=I.%20Novak&author=G.%20Sheean&author=BJ.%20S
inger&author=AB.%20Ward&journal=Eur%20J%20Neurol&volume=17&issue
=Suppl%202&pages=1-8&publication_year=2010)
3. Brashear A (2010) Botulinum toxin type A: exploring new indications. Drugs
Today (Barc) 46:671–682
CrossRef (https://doi.org/10.1358/dot.2010.46.9.1524356)

https://link.springer.com/article/10.1007/s10072-013-1357-1 2/9
21/10/2018 Relação de conversão entre Dysport e Botox na prática clínica: uma visão geral das evidências disponíveis | SpringerLink

Google Scholar (http://scholar.google.com/scholar_lookup?

title=Botulinum%20toxin%20type%20A%3A%20exploring%20new%20indicat
ions&author=A.%20Brashear&journal=Drugs%20Today%20%28Barc%29&vol
ume=46&pages=671-682&publication_year=2010)
4. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D (2009) Dose equivalence of
two commercial preparations of botulinum neurotoxin type A: time for a
reassessment? Curr Med Res Opin 25:1573–1584
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19463043)
CrossRef (https://doi.org/10.1185/03007990903028203)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Dose%20equivalence%20of%20two%20commercial%20preparations%20
of%20botulinum%20neurotoxin%20type%20A%3A%20time%20for%20a%20r
eassessment%3F&author=K.%20Wohlfarth&author=T.%20Sycha&author=D.%
20Ranoux&author=H.%20Naver&author=D.%20Caird&journal=Curr%20Med
%20Res%20Opin&volume=25&pages=1573-1584&publication_year=2009)
5. Park J, Lee MS, Harrison AR (2011) Profile of Xeomin® (incobotulinumtoxinA)
for the treatment of blepharospasm. Clin Ophthalmol 5:725–732
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21691580)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Profile%20of%20Xeomin%C2%AE%20%28incobotulinumtoxinA%29%20
for%20the%20treatment%20of%20blepharospasm&author=J.%20Park&autho
r=MS.%20Lee&author=AR.%20Harrison&journal=Clin%20Ophthalmol&volu
me=5&pages=725-732&publication_year=2011)
6. Pickett A (2011) Evaluating botulinum toxin products for clinical use requires
accurate, complete, and unbiased data. Clin Ophthalmol 5:1287–1290
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21966203)
CrossRef (https://doi.org/10.2147/OPTH.S24394)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Evaluating%20botulinum%20toxin%20products%20for%20clinical%20u
se%20requires%20accurate%2C%20complete%2C%20and%20unbiased%20da
ta&author=A.%20Pickett&journal=Clin%20Ophthalmol&volume=5&pages=12
87-1290&publication_year=2011)
7. Jost WH, Blümel J, Grafe S (2007) Botulinum neurotoxin type A free of
complexing proteins (XEOMIN) in focal dystonia. Drugs 67:669–683
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17385940)
CrossRef (https://doi.org/10.2165/00003495-200767050-00003)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Botulinum%20neurotoxin%20type%20A%20free%20of%20complexing%
20proteins%20%28XEOMIN%29%20in%20focal%20dystonia&author=WH.%
20Jost&author=J.%20Bl%C3%BCmel&author=S.%20Grafe&journal=Drugs&v
olume=67&pages=669-683&publication_year=2007)
8. Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin
preparations. Disabil Rehabil 29:1761–1768
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18033601)
CrossRef (https://doi.org/10.1080/09638280701568296)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Pharmacology%20of%20therapeutic%20botulinum%20toxin%20preparat

https://link.springer.com/article/10.1007/s10072-013-1357-1 3/9
21/10/2018 Relação de conversão entre Dysport e Botox na prática clínica: uma visão geral das evidências disponíveis | SpringerLink

ions&author=D.%20Dressler&author=R.%20Benecke&journal=Disabil%20Reh
abil&volume=29&pages=1761-1768&publication_year=2007)
9. Dressler D (2010) Botulinum toxin for treatment of dystonia. Eur J Neurol
17(Suppl 1):88–96
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20590814)
CrossRef (https://doi.org/10.1111/j.1468-1331.2010.03058.x)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Botulinum%20toxin%20for%20treatment%20of%20dystonia&author=D.
%20Dressler&journal=Eur%20J%20Neurol&volume=17&issue=Suppl%201&p
ages=88-96&publication_year=2010)
10. Hambleton P, Pickett AM (1994) Potency equivalence of botulinum toxin
preparations. J R Soc Med 87:719
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7837204)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Potency%20equivalence%20of%20botulinum%20toxin%20preparations&
author=P.%20Hambleton&author=AM.%20Pickett&journal=J%20R%20Soc%
20Med&volume=87&pages=719&publication_year=1994)
11. Pickett A, O’Keeffe R, Panjwani N (2007) The protein load of therapeutic
botulinum toxins. Eur J Neurol 14:e11
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17388970)
CrossRef (https://doi.org/10.1111/j.1468-1331.2007.01683.x)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=The%20protein%20load%20of%20therapeutic%20botulinum%20toxins&
author=A.%20Pickett&author=R.%20O%E2%80%99Keeffe&author=N.%20Pa
njwani&journal=Eur%20J%20Neurol&volume=14&pages=e11&publication_ye
ar=2007)
12. Wohlfarth K, Schwandt I, Wegner F et al (2008) Biological activity of two
botulinum toxin type A complexes (Dysport® and Botox®) in volunteers: a
double-blind, randomized, dose-ranging study. J Neurol 255:1932–1939
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18854916)
CrossRef (https://doi.org/10.1007/s00415-008-0031-7)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Biological%20activity%20of%20two%20botulinum%20toxin%20type%20
A%20complexes%20%28Dysport%C2%AE%20and%20Botox%C2%AE%29%20
in%20volunteers%3A%20a%20double-
blind%2C%20randomized%2C%20dose-
ranging%20study&author=K.%20Wohlfarth&author=I.%20Schwandt&author=
F.%20Wegner&journal=J%20Neurol&volume=255&pages=1932-
1939&publication_year=2008)
13. Wohlfarth K, Muller C, Sassin I et al (2007) Neurophysiological double-blind
trial of a botulinum neurotoxin type a free of complexing proteins. Clin
Neuropharmacol 30:86–94
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17414940)
CrossRef (https://doi.org/10.1097/01.WNF.0000240951.18821.50)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Neurophysiological%20double-
blind%20trial%20of%20a%20botulinum%20neurotoxin%20type%20a%20free

https://link.springer.com/article/10.1007/s10072-013-1357-1 4/9
21/10/2018 Relação de conversão entre Dysport e Botox na prática clínica: uma visão geral das evidências disponíveis | SpringerLink

%20of%20complexing%20proteins&author=K.%20Wohlfarth&author=C.%20
Muller&author=I.%20Sassin&journal=Clin%20Neuropharmacol&volume=30&
pages=86-94&publication_year=2007)
14. Hesse S, Lücke D, Malezic M et al (1994) Botulinum toxin treatment for lower
limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg
Psychiatry 57:1321–1324
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7964805)
CrossRef (https://doi.org/10.1136/jnnp.57.11.1321)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Botulinum%20toxin%20treatment%20for%20lower%20limb%20extensor
%20spasticity%20in%20chronic%20hemiparetic%20patients&author=S.%20H
esse&author=D.%20L%C3%BCcke&author=M.%20Malezic&journal=J%20Neu
rol%20Neurosurg%20Psychiatry&volume=57&pages=1321-
1324&publication_year=1994)
15. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA (1996) Use of botulinum
toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg
Psychiatry 61:30–35
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8676154)
CrossRef (https://doi.org/10.1136/jnnp.61.1.30)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Use%20of%20botulinum%20toxin%20in%20stroke%20patients%20with
%20severe%20upper%20limb%20spasticity&author=BB.%20Bhakta&author=
JA.%20Cozens&author=JM.%20Bamford&author=MA.%20Chamberlain&jour
nal=J%20Neurol%20Neurosurg%20Psychiatry&volume=61&pages=30-
35&publication_year=1996)
16. Simpson DM, Alexander DN, O’Brien CF et al (1996) Botulinum toxin type A in
the treatment of upper extremity spasticity: a randomized, double-blind,
placebo-controlled trial. Neurology 46:1306–1310
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8628472)
CrossRef (https://doi.org/10.1212/WNL.46.5.1306)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Botulinum%20toxin%20type%20A%20in%20the%20treatment%20of%2
0upper%20extremity%20spasticity%3A%20a%20randomized%2C%20double-
blind%2C%20placebo-
controlled%20trial&author=DM.%20Simpson&author=DN.%20Alexander&aut
hor=CF.%20O%E2%80%99Brien&journal=Neurology&volume=46&pages=130
6-1310&publication_year=1996)
17. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM (2000) Impact of
botulinum toxin type A on disability and carer burden due to arm spasticity
after stroke: a randomised double blind placebo controlled trial. J Neurol
Neurosurg Psychiatry 69:217–221
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10896696)
CrossRef (https://doi.org/10.1136/jnnp.69.2.217)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Impact%20of%20botulinum%20toxin%20type%20A%20on%20disability
%20and%20carer%20burden%20due%20to%20arm%20spasticity%20after%2
0stroke%3A%20a%20randomised%20double%20blind%20placebo%20control
led%20trial&author=BB.%20Bhakta&author=JA.%20Cozens&author=MA.%20

https://link.springer.com/article/10.1007/s10072-013-1357-1 5/9
21/10/2018 Relação de conversão entre Dysport e Botox na prática clínica: uma visão geral das evidências disponíveis | SpringerLink

Chamberlain&author=JM.%20Bamford&journal=J%20Neurol%20Neurosurg%
20Psychiatry&volume=69&pages=217-221&publication_year=2000)
18. Bakheit AM, Thilmann AF, Ward AB et al (2000) A randomized, double-blind,
placebo-controlled, dose-ranging study to compare the efficacy and safety of
three doses of botulinum toxin type A (Dysport) with placebo in upper limb
spasticity after stroke. Stroke 31:2402–2406
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11022071)
CrossRef (https://doi.org/10.1161/01.STR.31.10.2402)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=A%20randomized%2C%20double-blind%2C%20placebo-
controlled%2C%20dose-
ranging%20study%20to%20compare%20the%20efficacy%20and%20safety%2
0of%20three%20doses%20of%20botulinum%20toxin%20type%20A%20%28D
ysport%29%20with%20placebo%20in%20upper%20limb%20spasticity%20aft
er%20stroke&author=AM.%20Bakheit&author=AF.%20Thilmann&author=AB.
%20Ward&journal=Stroke&volume=31&pages=2402-
2406&publication_year=2000)
19. Hyman N, Barnes M, Bhakta B et al (2000) Botulinum toxin (Dysport)
treatment of hip adductor spasticity in multiple sclerosis: a prospective,
randomised, double blind, placebo controlled, dose ranging study. J Neurol
Neurosurg Psychiatry 68:707–712
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10811692)
CrossRef (https://doi.org/10.1136/jnnp.68.6.707)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Botulinum%20toxin%20%28Dysport%29%20treatment%20of%20hip%2
0adductor%20spasticity%20in%20multiple%20sclerosis%3A%20a%20prospec
tive%2C%20randomised%2C%20double%20blind%2C%20placebo%20controll
ed%2C%20dose%20ranging%20study&author=N.%20Hyman&author=M.%20
Barnes&author=B.%20Bhakta&journal=J%20Neurol%20Neurosurg%20Psychi
atry&volume=68&pages=707-712&publication_year=2000)
20. Pittock SJ, Moore AP, Hardiman O et al (2003) A double-blind randomised
placebo-controlled evaluation of three doses of botulinum toxin type A
(Dysport) in the treatment of spastic equinovarus deformity after stroke.
Cerebrovasc Dis 15:289–300
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12686794)
CrossRef (https://doi.org/10.1159/000069495)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=A%20double-blind%20randomised%20placebo-
controlled%20evaluation%20of%20three%20doses%20of%20botulinum%20to
xin%20type%20A%20%28Dysport%29%20in%20the%20treatment%20of%20
spastic%20equinovarus%20deformity%20after%20stroke&author=SJ.%20Pitt
ock&author=AP.%20Moore&author=O.%20Hardiman&journal=Cerebrovasc%
20Dis&volume=15&pages=289-300&publication_year=2003)
21. Woldag H, Hummelsheim H (2003) Is the reduction of spasticity by botulinum
toxin a beneficial for the recovery of motor function of arm and hand in stroke
patients? Eur Neurol 50:165–171
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14530623)
CrossRef (https://doi.org/10.1159/000073058)

https://link.springer.com/article/10.1007/s10072-013-1357-1 6/9
21/10/2018 Relação de conversão entre Dysport e Botox na prática clínica: uma visão geral das evidências disponíveis | SpringerLink

Google Scholar (http://scholar.google.com/scholar_lookup?

title=Is%20the%20reduction%20of%20spasticity%20by%20botulinum%20toxi
n%20a%20beneficial%20for%20the%20recovery%20of%20motor%20function
%20of%20arm%20and%20hand%20in%20stroke%20patients%3F&author=H.
%20Woldag&author=H.%20Hummelsheim&journal=Eur%20Neurol&volume=
50&pages=165-171&publication_year=2003)
22. Childers MK, Brashear A, Jozefczyk P et al (2004) Dose-dependent response to
intramuscular botulinum toxin type A for upper-limb spasticity in patients after
a stroke. Arch Phys Med Rehabil 85:1063–1069
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15241751)
CrossRef (https://doi.org/10.1016/j.apmr.2003.10.015)
Google Scholar (http://scholar.google.com/scholar_lookup?title=Dose-
dependent%20response%20to%20intramuscular%20botulinum%20toxin%20t
ype%20A%20for%20upper-
limb%20spasticity%20in%20patients%20after%20a%20stroke&author=MK.%
20Childers&author=A.%20Brashear&author=P.%20Jozefczyk&journal=Arch%
20Phys%20Med%20Rehabil&volume=85&pages=1063-
1069&publication_year=2004)
23. Brin MF (1997) Dosing, administration, and a treatment algorithm for use of
botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle
Nerve Suppl 6:S208–S220
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9826992)
CrossRef (https://doi.org/10.1002/(SICI)1097-4598(1997)6+
<208%3A%3AAID-MUS15>3.0.CO%3B2-1)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Dosing%2C%20administration%2C%20and%20a%20treatment%20algori
thm%20for%20use%20of%20botulinum%20toxin%20A%20for%20adult-
onset%20spasticity.%20Spasticity%20Study%20Group&author=MF.%20Brin&
journal=Muscle%20Nerve%20Suppl&volume=6&pages=S208-
S220&publication_year=1997)
24. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of
Botox and Dysport: a double blind, randomised, crossover study in cervical
dystonia. J Neurol Neurosurg Psychiatry 72:459–462
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11909903)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Respective%20potencies%20of%20Botox%20and%20Dysport%3A%20a
%20double%20blind%2C%20randomised%2C%20crossover%20study%20in%
20cervical%20dystonia&author=D.%20Ranoux&author=C.%20Gury&author=
J.%20Fondarai&author=JL.%20Mas&author=M.%20Zuber&journal=J%20Ne
urol%20Neurosurg%20Psychiatry&volume=72&pages=459-
462&publication_year=2002)
25. Odergren T, Hjaltason H, Kaakkola S et al (1998) A , randomised, parallel group
study to investigate the dose equivalence of Dysport and Botox in the treatment
of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6–12
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9436720)
CrossRef (https://doi.org/10.1136/jnnp.64.1.6)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=A%20%09%2C%20randomised%2C%20parallel%20group%20study%20t

https://link.springer.com/article/10.1007/s10072-013-1357-1 7/9
21/10/2018 Relação de conversão entre Dysport e Botox na prática clínica: uma visão geral das evidências disponíveis | SpringerLink

o%20investigate%20the%20dose%20equivalence%20of%20Dysport%20and%
20Botox%20in%20the%20treatment%20of%20cervical%20dystonia&author=
T.%20Odergren&author=H.%20Hjaltason&author=S.%20Kaakkola&journal=J
%20Neurol%20Neurosurg%20Psychiatry&volume=64&pages=6-
12&publication_year=1998)
26. Nüssgens Z, Roggenkämper P (1997) Comparison of two botulinum-toxin
preparations in the treatment of essential blepharospasm. Graefes Arch Clin
Exp Ophthalmol 235:197–199
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9143885)
CrossRef (https://doi.org/10.1007/BF00941758)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Comparison%20of%20two%20botulinum-
toxin%20preparations%20in%20the%20treatment%20of%20essential%20blep
harospasm&author=Z.%20N%C3%BCssgens&author=P.%20Roggenk%C3%A4
mper&journal=Graefes%20Arch%20Clin%20Exp%20Ophthalmol&volume=23
5&pages=197-199&publication_year=1997)
27. Sampaio C, Ferreira JJ, Simões F et al (1997) DYSPORT: a single-blind,
randomized parallel study to determine whether any differences can be detected
in the efficacy and tolerability of two formulations of botulinum toxin type A—
Dysport and Botox—assuming a ratio of 4:1. Mov Disord 12:1013–1018
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9399229)
CrossRef (https://doi.org/10.1002/mds.870120627)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=DYSPORT%3A%20a%20single-
blind%2C%20randomized%20parallel%20study%20to%20determine%20whet
her%20any%20differences%20can%20be%20detected%20in%20the%20effica
cy%20and%20tolerability%20of%20two%20formulations%20of%20botulinum
%20toxin%20type%20A%E2%80%94Dysport%20and%20Botox%E2%80%94a
ssuming%20a%20ratio%20of%204%3A1&author=C.%20Sampaio&author=JJ.
%20Ferreira&author=F.%20Sim%C3%B5es&journal=Mov%20Disord&volume
=12&pages=1013-1018&publication_year=1997)
28. Bentivoglio AR, Ialongo T, Bove F, De Nigris F, Fasano A (2012) Retrospective
evaluation of the dose equivalence of Botox® and Dysport® in the management
of blepharospasm and hemifacial spasm: a novel paradigm for a never ending
story. Neurol Sci 33:261–267
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21710123)
CrossRef (https://doi.org/10.1007/s10072-011-0672-7)
Google Scholar (http://scholar.google.com/scholar_lookup?
title=Retrospective%20evaluation%20of%20the%20dose%20equivalence%20o
f%20Botox%C2%AE%20and%20Dysport%C2%AE%20in%20the%20managem
ent%20of%20blepharospasm%20and%20hemifacial%20spasm%3A%20a%20n
ovel%20paradigm%20for%20a%20never%20ending%20story&author=AR.%2
0Bentivoglio&author=T.%20Ialongo&author=F.%20Bove&author=F.%20Nigri
s&author=A.%20Fasano&journal=Neurol%20Sci&volume=33&pages=261-
267&publication_year=2012)

Informações sobre direitos autorais

https://link.springer.com/article/10.1007/s10072-013-1357-1 8/9
21/10/2018 Relação de conversão entre Dysport e Botox na prática clínica: uma visão geral das evidências disponíveis | SpringerLink

© Springer-Verlag Italia 2013

Sobre este artigo
Cite this article as:
Ravenni, R., De Grandis, D. & Mazza, A. Neurol Sci (2013) 34: 1043. https://doi.org/10.1007/s10072-013-
1357-1

Recebido em 20 de setembro de 2012

Aceito 06 de março de 2013
Primeiro on-line 11 de abril de 2013
DOI https://doi.org/10.1007/s10072-013-1357-1
Nome da editora Springer Milan
Imprimir ISSN 1590-1874
ISSN 1590-3478 em linha

Sobre esta revista

Reimpressões e permissões

a Sociedade Neurológica Italiana

Publicado em cooperação com

a Sociedade Neurológica Italiana

Recomendações personalizadas

© 2018 Springer Nature Suíça AG. Parte da natureza de Springer .

Não autenticado Não afiliado 177.80.1.28

https://link.springer.com/article/10.1007/s10072-013-1357-1 9/9